A1 Refereed original research article in a scientific journal
New inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1
Authors: Messinger J, Hirvela L, Husen B, Kangas L, Koskimies P, Pentikainen O, Saarenketo P, Thole H
Publisher: ELSEVIER IRELAND LTD
Publication year: 2006
Journal name in source: MOLECULAR AND CELLULAR ENDOCRINOLOGY
Journal acronym: MOL CELL ENDOCRINOL
Volume: 248
Issue: 1-2
First page : 192
Last page: 198
Number of pages: 7
ISSN: 0303-7207
DOI: https://doi.org/10.1016/j.mce.2005.11.044(external)
Abstract
The estradiol-synthesizing enzyme 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta HSD1) is mainly responsible for the conversion of estrone (E1) to the potent estrogen estradiol (E2). It is a key player to control tissue levels of E2 and is therefore an attractive target in estradiol-dependent diseases like breast cancer or endometriosis.We selected a unique non-steroidal pyrimidinone core to start a lead optimization program. We optimized this core by modulation of R1-R6. Its binding mode at the substrate-binding site of 17 beta HSD1 is complex and difficult to predict. Nevertheless, some basic structure-activity relationships could be identified. In vitro, the most active pyrimidinone derivative showed effective inhibition of recombinant human 17 beta HSD1 at nanomolar concentrations. In intact cells overexpressing the human enzyme, IC50 values in the lower micromolar range were determined. Furthermore, the pyrimidinone proved its use in vivo by significantly reducing 17 beta HSD1-dependent tumor growth in a new nude mouse model. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
The estradiol-synthesizing enzyme 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta HSD1) is mainly responsible for the conversion of estrone (E1) to the potent estrogen estradiol (E2). It is a key player to control tissue levels of E2 and is therefore an attractive target in estradiol-dependent diseases like breast cancer or endometriosis.We selected a unique non-steroidal pyrimidinone core to start a lead optimization program. We optimized this core by modulation of R1-R6. Its binding mode at the substrate-binding site of 17 beta HSD1 is complex and difficult to predict. Nevertheless, some basic structure-activity relationships could be identified. In vitro, the most active pyrimidinone derivative showed effective inhibition of recombinant human 17 beta HSD1 at nanomolar concentrations. In intact cells overexpressing the human enzyme, IC50 values in the lower micromolar range were determined. Furthermore, the pyrimidinone proved its use in vivo by significantly reducing 17 beta HSD1-dependent tumor growth in a new nude mouse model. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
UTU Research Portal